Revashnee Naidoo

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

M. Sznol, A. Shoushtari, J. Infante, 2020, Clinical Cancer Research.

Abstract 1673: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp

L. Collins, J. Sacco, J. Hassel, 2021, Immunology.

571 IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells

K. Ranade, E. Leach, Esra Güç, 2021, Journal for ImmunoTherapy of Cancer.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

F. Bushman, Melissa L. Johnson, B. V. Van Tine, 2023, Nature Medicine.